04925922 is referenced by 60 patents and cites 1 patents.

Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. For some of these compositions, an enhanced or potentiated efficacy is observed when the conjugates are administered along with a related, unconjugated monoclonal antibody.

Hybridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively. Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.

Title
Potentiation of cytotoxic conjugates
Application Number
468193
Publication Number
4925922
Application Date
May 8, 1989
Publication Date
May 15, 1990
Inventor
Patrick J Scannon
Davis
CA, US
Robert W Baldwin
Long Eaton
GB
Vera S Byers
San Francisco
CA, US
Agent
Townsend and Townsend
Assignee
Xoma Corporation
CA, US
IPC
A61K 39/395
View Original Source